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Abstract
Aortic stenosis is the most common valvular heart disease affecting up to 4% of the elderly
population. It can be associated with dilatation of the ascending aorta and subsequent dissection.
Post-stenotic dilatation is seen in patients with AS and/or aortic regurgitation, patients with a
haemodynamically normal bicuspid aortic valve and following aortic valve replacement.
Controversy exists as to whether to replace the aortic root and ascending aorta at the time of
aortic valve replacement, an operation that potentially carries a higher morbidity and mortality.
The aetiology of post-stenotic aortic dilatation remains controversial. It may be due to
haemodynamic factors caused by a stenotic valve, involving high velocity and turbulent flow
downstream of the stenosis, or due to intrinsic pathology of the aortic wall. This may involve an
abnormality in the process of extracellular matrix remodelling in the aortic wall including
inadequate synthesis, degradation and transport of extracellular matrix proteins.
This article reviews the aetiology, pathology and management of patients with post-stenotic aortic
dilatation.
Methods
An English literature search using Pubmed-Medline data-
base between 1960 and today was carried out. Key words
used included aortic valve, aortic stenosis, aortic dilata-
tion, bicuspid aortic valve, surgery and matrix metallopro-
teinase.
Definition
Aortic stenosis (AS) is the most common valvular heart
disease affecting up to 4% of the elderly population [1,2].
Post-stenotic aortic dilatation is defined as dilatation of
the vessel wall distal to the area of a partial stenosis. It
refers to dilatation of the ascending aorta, >4.0 cm, distal
to a stenotic/malformed aortic valve (AV). This dilatation
is usually progressive > 0.3 cm/year.
Aortic dilatation is thought to be a precursor to aortic dis-
section and rupture, both of which are potentially fatal.
Aetiology
Post-stenotic aortic dilatation has been shown to occur in
patients with AS/aortic regurgitation (AR), haemodynam-
ically normal bicuspid aortic valve (BAV) and following
aortic valve replacement (AVR). It does not appear to be
related to the degree of AS [3], although this study was
conducted on patients with a valve area < 2.0 cm2, and
appears to be independent of whether the patient has had
valve replacement [4]. This suggests a possible genetic
basis for the dilatation as well as the mechanical stresses
placed on the vessel wall downstream of a stenotic lesion.
Published: 03 March 2006
Journal of Cardiothoracic Surgery2006, 1:7 doi:10.1186/1749-8090-1-7
Received: 30 January 2006
Accepted: 03 March 2006
This article is available from: http://www.cardiothoracicsurgery.org/content/1/1/7
© 2006Wilton and Jahangiri; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Journal of Cardiothoracic Surgery 2006, 1:7 http://www.cardiothoracicsurgery.org/content/1/1/7
Page 2 of 11
(page number not for citation purposes)
BAV is an independent risk factor for both AS and progres-
sive aortic dilatation [5].
Aortic stenosis (AS)
Aortic stenosis is the most common valvular heart disease
and the third most common heart disease, after hyperten-
sion and coronary artery disease, in Europe and North
America. In the elderly the prevalence of aortic stenosis
has been reported to be up to 4%. Aortic sclerosis, the pre-
cursor of aortic stenosis, has been found in approximately
a third of patients over the age of 65 years [1,2]. In most
patients the underlying cause is calcific AS [6]. This is a
chronic progressive disease that begins with thickening
and calcification of the valve cusps without haemody-
namic significance and ends in heavily calcified, stiff
cusps that cause severe valve stenosis. Recent studies have
shown that this is not only a degenerative process due to
mechanical stress, but also an active process, involving
inflammation and lipid infiltration, similar to that seen in
atherosclerosis. Epidemiological studies have confirmed
that AS and atherosclerosis share several common risk fac-
tors: male sex, older age, hypertension, diabetes, smoking
and elevated levels of low-density lipoprotein (LDL) cho-
lesterol and lipoprotein(a) [1,7]. These observations have
led to the proposal of pharmacological strategies, already
used in atherosclerosis, e.g. angiotensin-converting
enzyme inhibitors and hydroxymethylglutaryl-coenzyme
A reductase inhibitors (statins), which may slow the pro-
gression of AS. However, the SALTIRE study [8] has shown
results contrary to this. This was a double-blind, placebo-
control trial (n = 155) in which patients were treated with
80 mg of atorvastatin or matched placebo. They were
assessed at follow up (median 25 months) for AS and AV
calcification by echocardiography and serum LDL choles-
terol. They concluded that intensive lipid-lowering ther-
apy did not halt the progression of calcific aortic stenosis
or induce its regression but that large, long-term, ran-
domised trials were needed.
Bicuspid aortic valve (BAV)
BAV is a common congenital abnormality found in
adults. It occurs in approximately 1–2% of the population
[9,10]. This compares to 0.8% of all other forms of con-
genital cardiac disease combined. The frequency of BAV is
higher in males (male: female ratio, 2:1). Approximately
a third of BAV patients develop serious complications.
Therefore, it causes more morbidity and mortality than
the combined effects of all other cardiac conditions
[9,11]. BAV is associated with premature valve stenosis,
regurgitation, infective endocarditis, ascending aortic
aneurysms and dissection. Nearly all patients with a BAV
will require valve surgery during their lifetime and it has
been suggested that an underlying congenitally mal-
formed valve is more common than a tricuspid aortic
valve (TAV) as the underlying cause for isolated AVR for
AS in adults [12].
Pathogenesis of BAV
Embryology
BAV is the result of abnormal aortic cusp formation in val-
vulogenesis. There is fusion of adjacent cusps to form a
single aberrant cusp, which is larger than the one remain-
ing normal-sized cusp but smaller than 2 normal cusps
combined. It is therefore likely that BAV is the result of a
complex developmental process and not simply the
fusion of 2 normal cusps. The larger leaflet has a false
commisure that, on histological examination, shows no
valve tissue. It is thought that congenital AV malforma-
tions maybe a phenotypic continuum of unicuspid
(severe form), bicuspid (moderate form), tricuspid (nor-
mal) and the rare quadricuspid forms [13,14].
BAV is associated with coarctation of the aorta, patent
ductus arteriosus and left main stem stenosis which sup-
ports a genetic cause for the disease [15,16]. There is also
a high incidence of familial clustering of BAV, compatible
with autosomal dominant inheritance with reduced pen-
etrance [17].
Flow related theory
This theory sites abnormal blood flow through the AV
during valvulogenesis resulting in abnormal cusp separa-
tion and the formation of a BAV. There is, however, no
concrete evidence to support this theory.
Support for intrinsic aortic disease leading to post-stenotic 
dilatation
Patients with BAV have a larger ascending aortic diameter
compared to age and sex-matched control subjects, irre-
spective of altered haemodynamics [18]. The left ventricu-
lar outflow tract, aortic cusps, arterial media of the
ascending aorta and aortic arch are all linked embryolog-
ically as they all originate from the neural crest [19]. Dis-
orders of the neural crest have also been implicated in the
development of cervicocephalic arterial dissection. A
familial cluster of aorto-cevicocephalic arterial dissection
and BAV has been described strengthening the theory of
an underlying neural crest defect in the development of
BAV [20].
Endothelium-derived nitric oxide (NO) plays a role in val-
vulogenesis as well as cell growth and apoptosis, post
developmental vascular remodelling and angiogenesis.
Mice deficient in endothelial NO synthase, which synthe-
sizes endothelium-derived NO, were found to have a sig-
nificantly high incidence of BAV [21]. This suggests that
the genetic determinants of BAV are linked to the genetic
determinants of arterial abnormalities.Journal of Cardiothoracic Surgery 2006, 1:7 http://www.cardiothoracicsurgery.org/content/1/1/7
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NO has also been implicated in regulating the expression
of matrix metalloproteinase-9 in the aortic wall of rats. It
may, therefore, be involved in the homeostasis between
matrix metalloproteinases (MMPs) and tissue inhibitors
of metalloproteinases (TIMPs); a deficiency of NO tend-
ing towards matrix degradation [22].
Gurvitz et al [23] studied 2 groups of patients, one with
isolated BAV (n = 76) and the other normal tricuspid AV
(TAV) (n = 41), under the age of 21 years old, diagnosed
using transthoracic echocardiography. Patients were
excluded if they had other cardiac anomalies, a diagnosis
of Turner's or Marfan's syndrome, or a surgical or catheter-
based aortic valve intervention. Aortic root dimensions at
the annulus, sinus of Valsalva, sinotubular junction (STJ)
and the proximal ascending aorta were assessed in the par-
asternal long-axis view in systole. The haemodynamic
state of the AV was evaluated using colour flow and spec-
tral Doppler. In normal subjects it was seen that aortic
root dimensions correlated well with height and body sur-
face area (BSA), better than with age. It was also seen that
at every level of the aortic root, in patients with isolated
BAV, independent of the functional state of the valve, the
diameter was significantly greater than normal TAV, but
within the normal range (Table 1).
Mean circumferential stress in the dilated ascending aorta
increases linearly with blood pressure and diameter. Dis-
tensibilty has been shown to be due mainly to the intrin-
sic elastic properties of the aorta itself. Different groups of
patients studied, including patients with Marfan's syn-
drome and BAV with associated aneurysm, have different
predicted distensibility. In patients with BAV, it was seen
that valve function did not influence either the elastic
properties or the distensibility of the aorta suggesting
again that it is the intrinsic abnormalities within the wall
of the aorta, and not abnormal flow patterns, which lead
to aortic dilatation [24].
Aortic dilatation associated with haemodynamically 
normal AV
Nkomo et al [25] carried out a community-based study to
determine whether the association between BAV and aor-
tic dilatation could be demonstrated in patients with BAV,
without significant stenosis or regurgitation. Patients were
identified by echocardiography. They were excluded if
there was evidence of AS, more than trivial AR, aortic
coarctation, or mitral, pulmonic or tricuspid valve disease,
cardiomyopathy, pericardial disease, Marfan's syndrome
or a family history of Marfan's syndrome, or any other
form of congenital heart disease. 44 patients were
matched to an equal number of controls with normal TAV
of the same age (mean 35 ± 13 years), sex (65% male) and
BSA. Aortic dimensions were measured at the annulus,
aortic sinus, proximal ascending aorta and aortic arch. It
was found that the dimensions of the aortic root were
Table 1: Mean z scores, in relation to height, in children with BAV compared to those with TAV.
Study N Ao Ann Ao Sinus STJ Asc Ao
BAV TAV BAV TAV BAV TAV BAV TAV BAV TAV
Gurvitz 23 7 64 1 2 . 001 . 601 . 203 . 30
p Value < 0.001 < 0.001 < 0.001 < 0.001
Ao Ann = aortic annulus, Ao Sinus = aortic sinus, STJ = sinotubular junction, Asc Ao = ascending aorta.
BAV = Bicuspid aortic valve, TAV = Tricuspid aortic valve
Table 2: Aortic dimensions (mm) in patients with haemodynamically normal AV.
Study N Ao Ann Ao Sinus Asc Ao Ao Arch
BAV TAV BAV TAV BAV TAV BAV TAV BAV TAV
Nkomo 25 44 44 23.2 21.6 33.5 30.3 33.3 27.9 24.2 25.3
p = 0.002 p = 0.0001 p = 0.0001 p = 0.16 (N/S)
Nistri 26 66 70 23.6 22.7 31.6 28.7 31.2 26.9 N/A N/A
p = N/S p < 0.001 p < 0.001
Cecconi 27* 162 162 15.4 14.4 22 19.5 23.7 18.6 15.1 14.4
p = N/S p < 0.01 p < 0.001 p = N/S
* Dimensions in mm/m2
Ao Ann = aortic annulus, Ao Sinus = aortic sinus, Asc Ao = ascending aorta, Ao Arch = aortic arch.
BAV = Bicuspid aortic valve, TAV = Tricuspid aortic valve
N/A = not applicable, N/S = not significantJournal of Cardiothoracic Surgery 2006, 1:7 http://www.cardiothoracicsurgery.org/content/1/1/7
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consistently larger in patients with BAV. The largest differ-
ence was seen in the dimensions of the proximal ascend-
ing aorta. There was no significant difference between the
BAV and control groups with respect to dimensions of the
aortic arch. Other studies have confirmed these findings,
of dilatation of the aortic root and ascending aorta in
patients with BAV, and have also shown that there is no
increased dilatation seen in the descending or abdominal
aorta [26,27] (Table 2).
Aortic dilatation associated with aortic stenosis
Crawford and Roldan [3] carried out a study to determine
the prevalence of dilated aortic root in patients with AS.
They studied the echocardiograms of 118 patients with
AS, with a valve area of <2.0 cm2. They were age-matched
to patients with aortic sclerosis, but no stenosis, and to
normal controls. The aortic root diameter at the annulus,
coronary sinus and STJ levels were measured using tran-
sthoracic echocardiography. Dilated aortas were defined
as 2 SDs above the mean values obtained in the normal
group. This study concluded that aortic root dilatation is
common in AS, but is not related to severity of the steno-
sis. They did not, however, make any comparison between
BAV and TAV. As stated earlier, one of the limitations of
this study is that only patients with a valve area < 2.0 cm2
were included in the study.
Morgan-Hughes et al [28] carried out a prospective study
measuring the aortic root and ascending aortic diameters,
using CT scan images, on patients (BAV, n = 10; TAV, n =
18) with severe AS prior to undergoing AVR. They con-
cluded that patients with BAV and pure, severe AS have
moderately dilated thoracic aorta compared to matched
TAV (p < 0.005) (Table 3).
Keane et al [29] carried out a retrospective study to com-
pare aortic size in BAV and controls with matched valvular
lesions (AS, AR or mixed lesions). They measured the
diameter of the left ventricular outflow tract (LVOT), sinus
of Valsalva, STJ and proximal ascending aorta using tran-
sthoracic echocardiograms. 118 consecutive patients with
BAV were compared to controls with TAV. Paired analysis
demonstrated significant aortic dilatation at all levels
measured in BAV patients, with all degrees of AS and/or
AR, compared to controls (Table 4). These differences
were seen despite the significantly older age of the control
group compared to the BAV group (mean 55.3 years
(TAV) and 43.9 years (BAV)). This study also confirms the
result mentioned above, that the degree of dilatation is
not related to the severity of AS. It suggests that post-sten-
otic dilatation is a feature of BAV but not of congenitally
normal valves. It supports the theory that this is due, in
part, to an underlying pathology within the aortic wall.
Aortic dilatation occurring post AVR
Patients that undergo AVR often have some degree of
ascending aortic dilatation. At present, replacing the aortic
root at the time of AVR is controversial as the risk of aortic
Table 3: Aortic dimensions (mm) in patients with AS
Study N Ao Ann Ao Sinus STJ
Crawford 3 No AS 108 25 36 30
Mild AS 47 25 36 36*
Moderate AS 29 24 36 36*
Severe AS 42 24 36 35*
BAV TAV BAV TAV BAV TAV BAV TAV
Morgan-Hughes 28 10 18 N/A N/A 41.1 33.8 39.1 31.1
p Value < 0.005 < 0.005
*p < 0.001 compared to normal/sclerotic AV.
Ao Ann = aortic annulus, Ao Sinus = aortic sinus, STJ = sinotubular junction.
BAV = Bicuspid aortic valve, TAV = Tricuspid aortic valve
N/A = not applicable.
Table 4: Aortic dimensions (mm) of matched patients with AS/AR/Mixed valve disease.
Study N Ao Sinus STJ Proximal Aorta
BAV TAV BAV TAV BAV TAV BAV TAV
Keane 29 77 77 37.4 35.1 35.4 33.4 36.1 34.0
p Value < 0.01 < 0.001 < 0.001
Ao Sinus = aortic sinus, STJ = sinotubular junction.
BAV = Bicuspid aortic valve, TAV = Tricuspid aortic valveJournal of Cardiothoracic Surgery 2006, 1:7 http://www.cardiothoracicsurgery.org/content/1/1/7
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dilatation following AVR is uncertain. Some studies have
been carried out to determine the natural history of
ascending aortic dilatation following AVR.
Yasuda et al [4] carried out a retrospective analysis of
patients (BAV n = 13, TAV n = 14), using echocardiogra-
phy, before and after AVR and 18 BAV patients without
AVR. Diameters were measured at the sinus of Valsalva,
STJ and the proximal ascending aorta. The annual dilata-
tion rate was calculated by dividing changes of diameter
during the follow-up period by the BSA and the observa-
tional interval. Aortic dilatation in BAV patients was seen
to be significantly faster than that of TAV at the proximal
aorta only (0.18 compared to -0.08 mm/m2/year). There
was no significant difference in the dilatation rates of BAV
patients with and without AVR (0.03 and 0.02 mm/m2/
year respectively). This study showed that AVR could not
prevent progressive aortic dilatation in BAV. However,
TAV patients did not show further aortic dilatation after
AVR. It therefore seems that haemodynamic factors are
not responsible for the ongoing dilatation in BAV.
Genetic/structural abnormality
Associations have been found between post-stenotic dila-
tion and genetic and structural abnormalities within the
AV and ascending aorta, as set out below. However, there
is a lack of randomised trial data to establish whether
these associations are in fact causal.
Fibrillin-1
Fibrillin-1 is a major protein component of extracellular
matrix fibrils, called microfibrils. The FBN1 gene, found
on chromosome 15, encodes for this large glycoprotein.
Vascular tissues with deficient fibrillin-1 microfibrils
release metalloproteinases. These enzymes weaken the
vessel wall by degrading the elastic matrix components
and leading to matrix disruption and consequent dilata-
tion of the vessel.
Marfan's syndrome results from mutations in the FBN1
gene. The most common cardiovascular complication of
this condition is progressive aortic root enlargement, ini-
tially occurring at the sinus of Valsalva, and ascending aor-
tic aneurysms. The aneurysms develop as a consequence
of disruption of the medial and adventitial elastin and
collagen in association with focci of cystic medial necrosis
of the medial smooth muscle. There is also seen to be
increased expression of MMPs (especially 2 and 9) within
the aneurysmal aorta and, to a lesser extent, the AV [30].
Fedak et al [31] carried out a study to assess the vascular
matrix remodelling in patients with BAV and its implica-
tion for aortic dilatation. Samples of aorta and pulmonary
artery were obtained from patients undergoing surgery
with BAV (n = 21) and TAV (n = 16). The amount of fibril-
lin-1, elastin and collagen was determined using quantita-
tive immunohistochemical analysis, using fluorescence
microscopy, for fibrillin-1, and hydroxyproline determi-
nation. Fibrillin-1 content was significantly reduced, in
both the aorta and pulmonary artery, of BAV patients
compared to that seen in TAV suggesting a systemic defi-
ciency of this. It was independent of valve function and
patient age. However, the amount of matrix components,
elastin and collagen, were unchanged. This decrease in the
amount of fibrillin-1 in the vasculature of patients with
BAV may trigger MMP production leading to matrix dis-
ruption and vascular dilatation.
Recent studies have demonstrated that there is a difference
in the expression of matrix proteins between the convexity
and concavity of the dilated aorta in patients with BAV
[32]. These results are consistent with the wall-stress
asymmetry that has also been reported by Robicsek and
colleagues [33]. They studied three explanted haemody-
namically normal congenitally BAV, where they used a
simulator to produce a computerised digital model. They
showed excessive folding and creasing persistent through-
out the cardiac cycle, extended area of leaflet contact, sig-
nificant morphologic stenosis and asymmetrical flow
patterns and turbulence. Furthermore, Richards et al [34]
studied the influence of structural geometry on the sever-
ity of BAV and stenosis using transthoracic, transoesopha-
geal echocardiography and computer simulations. They
demonstrated that for the same anatomic orifice area,
functional severity is greater in BAV than in degenerative
TAV patients with AS.
Matrix metalloproteinases (MMPs)
The MMPs are a family of proteases that play an important
role in the homeostasis of connective tissue. They are syn-
thesized by a variety of cell types including endothelial
and smooth muscle cells, fibroblasts and macrophages.
They are classified into classic MMPs and novel MMPs.
The classic MMPs are secreted as proenzymes and include
3 subgroups: (1) the interstitial collagenases (MMP-1,
MMP-8 and MMP-13), which degrade fibrillar collagen;
(2) the gelatinases (MMP-2 and MMP-9), which act on
type IV collagen and partially degrade fibrillar collagens as
well as elastin; and (3) stromelysins (MMP-3, MMP-7 and
MMP-10), which have a broad substrate specificity. A met-
alloelastase (MMP-12), which degrades elastin, is also
included in this group. The novel MMPs are secreted in
active form or are associated with the cell surface. The
activity of the MMPs is regulated by their interaction with
4 types of tissue inhibitors of metalloproteinases (TIMPs).
The balance between MMPs and TIMPs regulates the deg-
radation of extracellular matrix in normal and pathologi-
cal states [35-37]. TIMP-1 is the most common in the
aorta. It is a 25-kd polypeptide capable of inhibiting mostJournal of Cardiothoracic Surgery 2006, 1:7 http://www.cardiothoracicsurgery.org/content/1/1/7
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MMPs and is produced by fibroblasts or smooth muscle
cells.
Degradation of ECM, especially elastin, within the aortic
wall is a hallmark of abdominal aortic aneurysms (AAA).
Studies have identified increased expression of MMP-1,
MMP-2, MMP-9, TIMP-1, TIMP-2 and MMP/TIMP ratios
as an important factor in the aetiology of AAA formation.
However, the predominant MMP expressed in AAA is
MMP-9, produced by macrophages [38].
Elastin and collagen degradation in thoracic aortic aneu-
rysms is mediated by MMPs, particularly the gelatinases,
MMP-2 and MMP-9.
Le Maire et al [39] studied MMP expression in ascending
aortic aneurysms associated with BAV and TAV. Samples
of ascending aorta were obtained from 29 patients (BAV n
= 14, TAV n = 15). Histological and immunohistochemi-
cal analysis was carried out on the specimens. They
showed that ascending aortic aneurysms exhibited
increased MMP expression when compared to controls
(non-aneurysmal aortic tissue). The pattern of MMP
expression, however, differed between aneurysms associ-
ated with BAV and those with TAV. Another study, carried
out by Boyum et al [40], showed that there was an
increase in the level of MMP-2 and MMP-9 in thoracic aor-
tic aneurysms associated with BAV compared to TAV. They
did not, however, find any significant difference in the
expression of TIMP-1 or TIMP-2.
Most studies have looked at the increased expression of
MMPs within aneurysmal tissue. Ikonomidis et al [41]
studied the effects of deletion of the TIMP-1 gene on the
progression of murine thoracic aortic aneurysms (TAA).
They used adult wild-type and TIMP-1 knockout mice.
They showed that deletion of the TIMP-1 gene resulted in
an increase in size and continued progression of TAA for-
mation compared with wild-type mice. They concluded
that this was, at least in part, due to the alteration of the
balance between gelatinase activity and its endogenous
inhibition. These results suggest that therapeutic strategies
that can shift the MMP/TIMP stoichiometric balance away
from net proteolysis may be used to inhibit the incidence
and progression of TAA.
In diseased or degenerated congenitally deformed valves,
increased local MMP activity could alter their elastic and
collagen component leading to structural and functional
failure.
Histological and immunohistochemical analysis of the
AV in patients with nonrheumatic TAV and AS revealed an
inflammatory infiltrate within the AV leaflets and an
increase in expression of MMP-1, MMP-2 and MMP-3 in
AV of patients with severe AS. It was also found that MMP-
9 was only present in the leaflets of patients with AS
[42,43].
Koullias et al [44] carried out a study to semiquanitatively
analyse the expression of MMPs (1, 2 and 9) and TIMPs (1
and 2) in AV tissue. The study group consisted of 26
patients, undergoing surgery for AS, AR, ascending aortic
aneurysm or type A dissection (BAV n = 10, TAV n = 16,
controls n = 4). They showed that MMP-9 expression was
significantly higher in BAV compared to normal and dis-
eased TAV. This increased proteolytic presence in BAV
may lead to the observed decrease in elastin and collagen
content and their resultant functional failure. Others have
reported similar results [45].
In summary, these findings suggest that an increase in
MMP expression in the aorta of BAV patients may explain
the predilection to aneurysm formation. Therefore, by
modifying the MMP activity, it maybe possible to reduce
or prevent the progression of thoracic aortic aneurysms
(TAA). There may also be a role for altering the expression
of MMPs to help reduce the progression of BAV disease.
Histological abnormalities
Congenital BAV is associated with cystic medial necrosis,
that is, necrosis of the medial smooth muscle cells and
accumulation of proteoglycan, of the aorta. De Sa et al
[46] examined the histological changes in the ascending
aorta and pulmonary trunk in patients with BAV. They
studied 31 patients (BAV, n = 20 and TAV, n = 11) under-
going AVR. Samples of ascending aorta and pulmonary
trunk were collected at the time of surgery. The degenera-
tive changes (medionecrosis, fibrosis, cystic medial necro-
sis (mucoid material accumulation), changes in smooth
muscle cell orientation and elastic fragmentation) in the
ascending aorta and pulmonary trunk of patients with
BAV disease were significantly more severe than in TAV
patients. This severity was mainly related to degree of
cystic medial necrosis, smooth muscle cell changes and
elastic fragmentation. These findings may explain aortic
root and ascending aortic dilatation in patients with BAV
disease and pulmonary autograft dilation in certain
patients following the Ross procedure.
Ascending aortic dilatation post AVR
Replacement of the ascending aorta at the time of AVR is
controversial because the risk of progressive dilatation fol-
lowing AVR is uncertain (Table 5). Andrus et al [47] set
out to determine the natural history of ascending aorta
dilatation following AVR. They studied 185 patients
undergoing AVR. They measured the ascending aortic
diameter, 2 cm above the sinotubular ridge, using tran-
sthoracic echocardiography before surgery and during the
follow-up period. Progressive aortic dilatation wasJournal of Cardiothoracic Surgery 2006, 1:7 http://www.cardiothoracicsurgery.org/content/1/1/7
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defined as an increase in diameter of >0.3 cm from the
preoperative measurement. This was observed in only
15% of the study population. No patients with baseline
aortic dilatation (3.5–5.3 cm) dilated > 5.5 cm during the
follow-up period (n = 107, mean 33.6 months). They
found no clinical or valvular characteristics that predicted
progressive aortic dilatation. Their conclusion was there-
fore against routine replacement of the ascending aorta at
the time of AVR.
Another clinical study, by Matsuyama et al [48], looked at
the incidence of aortic complications in 35 patients fol-
lowing AVR, with a preoperative dilated ascending aorta =
4.0 cm, assessed by computed tomography or operative
findings. The baseline aortic diameter in the study popu-
lation ranged from 4.0–5.5 cm. The mean follow -up
period was 8.1 ± 3.5 years (range: 2.3–13 years). Aortic
events occurred in 5 patients (1 aortic dissection, 2 aortic
rupture and 2 reoperations). These complications
occurred in patients with baseline aortic diameters 4.7–
5.0 cm. The authors concluded that the clinical course of
patients with dilated ascending aorta is unpredictable and
may occur even in patients with a baseline aortic diameter
< 5.0 cm. They concluded that preventative aortic surgery
at the time of AVR should be considered, to prevent aortic
rupture and dissection, in patients with ascending aorta of
4.0–5.0 cm.
As mentioned earlier, Yasuda et al [4] showed that AVR in
patients with BAV did not prevent progressive dilatation
of the ascending aorta.
Surgical implications
At present there is controversy over the best management
for mild to moderate aortic dilatation associated with AV
disease, especially BAV. This is partly due to the lack of
concrete evidence for progressive dilatation following
AVR and partly due to the increased risk associated with
aortic root replacement (ARR).
A retrospective study carried out by Shapira et al [49] over
a 10 year period (1987–1997) showed that advances in
non-invasive diagnosis and improved perioperative man-
agement has lead to a decrease in morbidity and mortality
of patients undergoing surgery on the proximal aorta with
the operative mortality of thoracic aortic aneurysm repair
reduced from between 9–17% to 2.6%.
Should the ascending aorta be replaced in patients with 
BAV?
AVR is the treatment of choice for patients with sympto-
matic AV disease. Current recommendations for the surgi-
cal replacement of ascending aortic aneurysms are
diameter >5.5 cm or = 5.0 cm in patients with Marfan's
syndrome [50]. Borger et al [51] studied 201 patients with
BAV (mean age 56 ± 15 years) who underwent AVR.
Patients were excluded if they had concomitant ascending
aorta replacement. All BAV with ascending aorta > 5.0 cm
had ascending aortic replacement and were therefore
excluded. During the follow-up period of 10.3 years, 22
patients had long-term complications related to the
ascending aorta including replacement of ascending aorta
for aneurysm (n = 18), dissection (n = 1) and sudden car-
diac death (n = 3). 44 patients had reoperations, mainly
for AV prosthesis failure. The 15-year freedom from
ascending aorta-related complications was 86%, 81% and
43% in patients with an aortic diameter of <4.0 cm, 4.0–
4.4 cm and 4.5–4.9 cm respectively. The authors therefore
concluded that patients undergoing AVR for BAV disease
should have their ascending aorta replaced if the preoper-
ative diameter is >4.5 cm.
Ubranski et al [52] carried out a case-matched study that
showed that replacement of the ascending aorta and AV
can be performed with similar operative risk, valve-related
mortality and late cardiac mortality as isolated AVR. They
analysed 100 patients with AV disease and aneurysm
(diameter >4.5 cm) of the aorta who underwent AVR and
ascending aorta replacement (± complete root) and a
Table 5: Ascending aorta dilatation rate following AVR
Study N F/U (mo) Expansion Rate (cm/year)
Andrus 47 185 30.0 -0.03*
107 33.6 -0.01*
BAV TAV BAV TAV
21 164 30.0 +0.14 ** -0.05
Matsuyama 48 35 97.2 +0.058*
Yasuda 4 BAV TAV BAV TAV
13 14 116.4 +0.018*** -0.008
cm/(m2/yr) cm/(m2/yr)
*p = N/S, **p = 0.06, ***p = 0.03
BAV = Bicuspid aortic valve, TAV = Tricuspid aortic valve
F/U (mo) = follow-up (months)Journal of Cardiothoracic Surgery 2006, 1:7 http://www.cardiothoracicsurgery.org/content/1/1/7
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matched group of patients undergoing just an AVR. There
was no significant difference in the early mortality. 5-year
survival seen in the ARR group was 60.7% compared to
86.3% in the AVR group (p = 0.13). At a mean follow-up
period of 37 ± 17 months the freedom from cardiac
deaths was almost identical in both groups. Similarly,
Sundt and colleagues [53] in a retrospective analysis com-
paring ARR with separate valve and ascending aorta
replacement reported no significant difference in early
mortality, but showed better survival for the complete
root replacement at 5.6 years follow-up (p = 0.04).
Another surgical approach suggested for the management
of BAV, associated with a dilated ascending aorta < 5.5 cm,
is to carry out AVR with wrapping of the ascending aorta.
This method has a low morbidity and mortality rate and
was seen to decrease the risk of further dilatation, aneu-
rysm formation and dissection [54,55]. More recently this
procedure has been carried out using an external support
made to fit the patient's aorta. This was done using digital
information from magnetic resonance images to make a
replica of the patient's aorta and then computer-aided
design to produce the tailored graft [56].
Suitability of the Ross procedure in BAV
The Ross and Ross-Konno procedure allows the replace-
ment of a stenotic or regurgitant AV in children and young
adults with congenital AV disease. Dilatation of the pul-
monary autograft root is a common complication follow-
ing the Ross procedure. The pulmonary and aortic roots
share a common embryological origin and it has been
proposed that the dilatation of the pulmonary autograft
may occur as a result of an intrinsic abnormality within
the wall, as seen in the aorta of patients with congenital
AV disease [57]. This theory is supported by the findings
of de Sa et al [46], that the degenerative changes in the
ascending aorta and pulmonary trunk of patients with
BAV were more severe than those with TAV. However, this
result has been contradicted by Schmid et al [58], who
failed to show an association between morphological
abnormalities in the dilated aorta and pulmonary artery,
in patients with either BAV or TAV. They did, however,
confirm the finding of more severe degenerative changes
in the aorta associated with BAV. Risk factors for late dila-
tation of the pulmonary autograft include younger
patients, preoperative aortic aneurysm, BAV and those
having ARR without support of the annulus and STJ
[57,59]. Inclusion techniques have also been described
whereby the pulmonary aoutograft is encased in a Dacron
tube to prevent dilatation [60].
Hraska et al [61] analysed the mid-term results of 66 chil-
dren who had undergone the Ross procedure. The mortal-
ity rate approached zero in both simple and complex left
heart lesions, including infants and neonates. Their main
concern was dilatation of the neo-aortic root leading to
progression of AR, especially in patients with BAV. Bogers
and colleagues analysed 123 patients, 81 with BAV who
underwent the Ross procedure at a median follow-up of
5.3 years. Freedom from allograft and autograft interven-
tion was similar in both groups [62].
Other therapeutic modalities
B-blockers
B-blockers decrease the sheer stress of the vessel wall distal
to a stenotic lesion. B-blockers are used as long-term ther-
apy in Marfan's syndrome to reduce the rate of pressure
change in the aortic root. This is achieved by using their
negative inotropic and chronotropic effects to reduce the
impulse of the left ventricular ejection and decrease the
heart rate. This has been shown to decrease the rate of aor-
tic dilatation and reduce the development of aortic com-
plications [63]. However, no studies have been carried out
in BAV patients.
In animal models of AR β-blockers have been shown to
reduce the ventricular dilatation and improve remode-
ling.
Angiotensin-converting enzyme (ACE) inhibitors and 
statins
Aortic stenosis and atherosclerosis share several common
risk factors: male sex, older age, hypertension, diabetes,
smoking and elevated levels of low-density lipoprotein
(LDL) cholesterol and lipoprotein(a) [1,7]. These obser-
vations have led to the proposal of pharmacological strat-
egies, already used in atherosclerosis, e.g. ACE inhibitors
and hydroxymethylglutaryl-coenzyme A reductase inhibi-
tors (statins), which may slow the progression of AS.
ACE has been shown to play an important role in devel-
opment of atherosclerosis, presumably via its proinflam-
matory effects. ACE has been found to be present in aortic
sclerotic and stenotic valves, but is not found in normal
aortic valves, where it may participate in lesion develop-
ment, as is evidenced by the presence of its enzymatic
product, angiotensin II. The observed association between
ACE and LDL in both lesions and plasma suggests that
LDL may deliver ACE to the lesions [64]. It has previously
been shown that ACE inhibitors slow calcium accumula-
tion in aortic valves but a recent study found that ACE
inhibitors did not slow the haemodynamic progression
rate of AS [65].
Statins are used in the prevention and treatment of athero-
sclerosis by reducing the levels of LDL cholesterol and
lipoprotein(a). Statins have also been shown to slow aor-
tic valve calcium accumulation and a recent study has
found that they significantly reduce the haemodynamic
progression of both mild-moderate and severe aortic ste-Journal of Cardiothoracic Surgery 2006, 1:7 http://www.cardiothoracicsurgery.org/content/1/1/7
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nosis. This rate of haemodynamic progression was unre-
lated to cholesterol levels and it is therefore thought that
the effects of statins at the valvular level maybe due to
their pleiotropic or anti-inflammatory properties rather
than by their cholesterol-lowering effects [66]. However,
as stated previously, the SALTIRE study group [8] found
that treatment with atorvastatin did not halt the progres-
sion of calcific aortic stenosis or induce its regression. The
anti-inflammatory effects, independent of their lipid-low-
ering effects, of statins have also been implicated as the
mechanism by which they have been shown to suppress
the development of experimental abdominal aortic aneu-
rysms (AAA) in normal and hypercholesterolaemic mice.
AAAs are associated with atherosclerosis, chronic inflam-
mation and matrix metalloproteinase (MMP)-mediated
connective tissue destruction. Statins were shown to pre-
serve the medial elastin and smooth muscle cells and to
alter the aortic wall expression of MMPs and their inhibi-
tors [66].
Calcium antagonists
These have been used in Marfan's syndrome to reduce the
rate of dilatation of the aortic root [67]. No studies have
yet been carried out in BAV patients but they may have a
role in decreasing the rate of post-stenotic dilatation.
N-terminal B-type natriuretic peptide
B-type natriuretic peptide (BNP) and N-terminal BNP
(NtBNP) are neurohormones synthesized and secreted
mainly by the ventricular myocardium. An increase in
synthesis of NtBNP is associated with wall stress. Natriu-
retic peptides have been reported to be independent pre-
dictors of outcome in congestive heart failure, primary
pulmonary hypertension, acute myocardial infarction and
pulmonary embolism. Plasma levels of natriuretic pep-
tides are known to be related to disease severity and symp-
tomatic status in AS [68,69] and now preoperative NtBNP
has been shown to predict postoperative outcome with
regard to survival, symptomatic status and left ventricular
function in severe AS [70]. As yet, this has not been meas-
ured in aortic disease.
Synthetic MMP inhibitors (MMPIs)
The MMPs are involved in many physiological functions
and, therefore, general inhibition may not be feasible and
specific inhibition may be required. The activity of MMPs
is kept under tight control at the level of transcription,
activation of latent proenzymes and inhibition of proteo-
lytic activity. Modulation of MMP regulation can occur at
various biochemical sites. Therapeutic manipulation of
the extracellular matrix has been used in other disease
processes, including arthritis and malignancy. Possible
mechanisms of MMP inhibition include: increasing the
levels of the naturally occurring inhibitors (TIMPs), by
either exogenous administration of recombinant TIMPs
or by increasing their local production; administration of
synthetic inhibitors; and decreasing the production of
MMPs.
Synthetic inhibitors of MMPs have been investigated in
other disease processes, including the use of minocycline
in rheumatoid arthritis, and several are currently under
investigation for the use in cardiovascular disease [35].
Conclusion
Post-stenotic aortic dilatation is most commonly seen in
patients with a BAV. The degree of this dilatation, how-
ever, may not be related to the degree of AS and does not
appear to be influenced by the occurrence of AVR. It is
likely that the dilatation of the ascending aorta is due,
mainly, to intrinsic pathology within the aortic wall rather
than the haemodynamic effects of a dysfunctional AV.
There is controversy as to whether the ascending aorta
should be replaced at the time of initial AV surgery, if the
diameter of the aorta is < 5.5 cm. Most of the evidence
suggests that the aorta will continue to dilate at an
unknown rate. With improvements of surgical technique
and perioperative management resulting in decreased
morbidity and mortality following ARR, replacement of
the ascending aorta should probably be considered for
diameters of 4.5 – 5.5 cm. Other therapeutic strategies
being investigated that may reduce the rate of dilation are
β-blockers, statins and the new synthetic MMP inhibitors.
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